Epigenetic analysis of body fluids and tumor tissues: Application of a comprehensive molecular assessment for early-stage breast cancer patients

Annals of the New York Academy of Sciences

Volumn 1075, Issue , 2006, Pages 211-221

  Taback, Bret ^a   Giuliano, Armando E ^b   Lai, Ron ^b   Hansen, Nora ^b   Singer, Frederick R ^b   Pantel, Klaus ^c   Hoon, Dave S B ^b  

^a NewYork Presbyterian Hospital   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bone marrow; Breast cancer; Methylation

Indexed keywords

DNA MARKER; MOLECULAR MARKER;

BODY FLUID; BONE MARROW BIOPSY; BREAST CANCER; BREAST METASTASIS; BREAST TUMOR; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLONAL VARIATION; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DNA DETERMINATION; DNA METHYLATION; EARLY CANCER; EARLY DIAGNOSIS; EPIGENETICS; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MGMT GENE; NUCLEIC ACID ANALYSIS; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; QUANTITATIVE METHYLATION SPECIFIC PCR; RAR BETA2 GENE; RASSF1A GENE; RNA METHYLATION; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; SERUM; TUMOR DIAGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 33749571963     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1368.029     Document Type: Conference Paper

References (25)

1. FISHER, B. et al. 1989. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320: 479-484.
2. ROSEN, P.R. et al. 1989. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J. Clin. Oncol. 7: 355-366.
3. GOLDHIRSCH, A. et al. 1988. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J. Clin. Oncol. 6: 89-97.
4. MOLINO, A. et al. 1991. A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. Cancer 67: 1033-1036.
5. BRAUN, S. et al. 2000. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 342: 525-533.
6. SIDRANSKY, D. 1997. Nucleic acid-based methods for the detection of cancer. Science 278: 1054-1059.
7. SILVA, J.M. et al. 1999. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res. 59: 3251-3256.
8. TABACK, B. et al. 2001. Microsatellite alterations detected in the serum of early stage breast cancer patients. In circulating nucleic acids in plasma/serum ii. Ann. N. Y. Acad. Sci. 945: 22-30.
9. SILVA, J.M. et al. 2002. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin. Cancer Res. 8: 3761-3766.
10. LO, Y.M. et al. 1999. Quantitative analysis of aberrant p 16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res. 59: 3899-3903.
11. ESTELLER, M. et al. 2001. A gene hypermethylation profile of human cancer. Cancer Res. 61: 3225-3229.
12. MULLER, H.M. et al. 2003. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res. 63: 7641-7645.
13. TABACK, B. et al. 2003. Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients. Cancer Res. 63: 1884-1887.
14. HOON, D.S. et al. 2004. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23: 4014-4022.
15. LEHMANN, U. et al. 2002. Quantitative assessment of promoter hypermethylation during breast cancer development. Am. J. Pathol. 160: 605-612.
16. DAMMANN, R. etal. 2001. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), aputative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res. 61: 3105-3109.
17. JIN, Z. et al. 2001. Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br. J. Cancer. 85: 69-73.
18. NASS, S.J. et al. 2000. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res. 60: 4346-4348.
19. HERMAN, J.G. et al. 1996. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93: 9821-9826.
20. WIDSCHWENDTER, M. et al. 2000. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J. Natl. Cancer Inst. 92: 826-832.
21. WIDSCHWENDTER, M. & P.A. JONES. 2002. DNA methylation and breast carcinogenesis. Oncogene 21: 5462-5482.
22. MEHROTRA, J. et al. 2004. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res. 10: 3104-3109.
23. EVRON, E. et al. 2001. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357: 1335-1336.
24. KRASSENSTEIN, R. et al. 2004. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin. Cancer Res. 10: 28-32.
25. SCHWARZENBACH, H. et al. 2004. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Ann. N. Y. Acad. Sci. 1022: 25-32.